Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs AMC ENTERTAINMENT HOLDINGS, INC. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.61 (market cap $2.26B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.2× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AMC | |
|---|---|---|
Market Cap | $5.07B | $2.26B |
Sector | Health | Media |
52-Week High | $29.45 | $3.15 |
52-Week Low | $20.06 | $0.95 |
Enterprise Value | $4.19B | $9.20B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
AMC trades at $2.63, up 9.58% today, showing strong momentum after recent earnings beats. The stock is technically bullish with positive moving averages and approaching key resistance at $3.00. Fundamentally, while revenue grew to $4.85B in 2025, the company posted a net loss of $632.4M, though recent quarters show improving performance with three consecutive EPS beats. Analyst sentiment is mixed with a $3.00 consensus target, and positive news highlights record box office performance and international growth.
Outlook remains cautiously optimistic as AMC benefits from theater industry recovery and premium screen strategy, but significant risks persist including high debt load, negative equity, and volatile cash flow. The stock offers speculative upside if operational improvements continue, but investors should weigh the substantial financial challenges against recent positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →
